TNI Biotech Expands Partnership with Hubei Qianjiang Pharma

TNI BioTech of Florida expanded its relationship with Hubei Qianjiang Pharma (SHA: 600568) by signing an agreement that will speed up development of IRT-101 (MENK). TNI discovered MENK, an immunotherapy for cancer and autoimmune diseases. In 2012, Qianjiang in-licensed China rights to the drug. According to TNI, the partnership combines the drug development expertise of its subsidiary Cytocom, with Qianjiang’s financial, manufacturing and distribution capabilities. More details.... Stock Symbol: (OTC: TNIB) Share this with colleagues: // //